Antler Raises Over $300m and Expands Investment Focus to Invest Up to Series C
13.10.2021 16:05:00 EEST | Business Wire | Press release
Global venture capital firm Antler has announced that it has closed over $300m to date, allowing it an opportunity to provide continued support to its companies in subsequent funding rounds. Investors in the funds include Schroders, Vækstfonden, and Phoenix Group.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211013005689/en/
Antler's Demo Day in London (Photo: Business Wire)
Antler is on a mission to fundamentally improve the world by enabling and investing in the world's most exceptional people. The primary focus of the firm will remain investing at the pre-seed stage, with the firm now also having the ability to offer its portfolio companies follow-on capital as they grow and scale, up to Series C.
Magnus Grimeland, CEO and Founder of Antler, said “We continue to provide support for our founders from the earliest stages, and are thrilled to be able to continue investing in them as they grow. We look forward to backing even more entrepreneurs that are redefining industries in the future.”
Antler is continually developing and expanding its senior team, and its global presence. To this end, Antler has recruited new partners Naman Budhdeo, Erik Jonsson, Jiho Kang, and Subir Lohani to lead its new Canada, Vietnam, Korea, and Indonesia teams respectively.
Teddy Himler from SoftBank also joins as a Partner of the later-stage investment team.
Antler has invested in over 350 companies globally across over 30 different industries since 2018. Of these companies, 40% have at least one female co-founder, with 70 nationalities represented.
Antler continues to invest in its portfolio companies as they scale. The firm has a global network of over 600 expert advisors, and an online platform of resources, tools and supports its portfolio companies with introductions to global investors, hands-on assistance with new market entry, and access to a global network of expert advisors.
In providing continued support and investment, Antler confirms its position as a long-term partner for exceptional entrepreneurs -- from the outset of their journey, to the later stages as they scale.
Antler also intends to now invest in a number of companies from outside of its portfolio at seed and Series A stages. Antler has put together a team to oversee on-going investments, led by Antler partners: Martell Hardenberg, Co-Founder of Lazada; Teddy Himler, formerly of SoftBank; Stefan Jung, previously Managing Partner at Venturra Capital; and Navi Singh, a Researcher at MIT's Department of Mechanical Engineering.
This on-going evolution is built on what we believe to be a strong structural advantage in deal flow sourcing from regionally focused early-stage investments across 15 countries in 5 continents, including: Australia (Melbourne and Sydney), Canada (Toronto), Denmark (Copenhagen), Germany (Berlin), India (Bangalore), Indonesia (Jakarta), Kenya (Nairobi), Norway (Oslo), Sweden (Stockholm), Singapore, South Korea (Seoul), The Netherlands (Amsterdam), The UK (London), US (Austin and New York), and Vietnam (Ho Chi Minh).
Lieven Debruyne, Global Head of Distribution at Schroders said, “As a longstanding partner and investor in Antler, we are delighted to continue our investment in Antler. It is a unique opportunity to gain exposure to a global growth portfolio of innovative technology companies, and to ensure a steady stream of capital is being invested in companies that will define how we all live and work in the future”
Lars Nordal Jensen, Senior Director at Vækstfonden said, “We are thrilled to continue our commitment to Antler. We have previously invested in Antler, and have been delighted with the firm’s overwhelmingly positive contribution to the technology ecosystem since their market entry. In Vaekstfonden we want to help drive innovation and new technology, and therefore we are very pleased to see Antler continue its commitment to supporting innovative founders throughout their journey”
THIS PRESS RELEASE IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES. NO OFFERING OF INTERESTS OF THE FUNDS REFERRED TO ABOVE HAS BEEN OR WILL BE REGISTERED UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OR UNDER ANY OTHER U.S. FEDERAL AND STATE SECURITIES LAWS, AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED IN THE UNITED STATES OR TO U.S. INVESTORS, UNLESS THEY ARE REGISTERED, OR EXEMPT FROM, OR NOT SUBJECT TO, REGISTRATION UNDER THE SECURITIES ACT.
-ENDS-
About Antler
Antler is a global early-stage venture capital firm that invests in the defining technology companies of tomorrow. The firm has offices globally across most major entrepreneurial hubs, including in London, Berlin, Stockholm, New York, Singapore and Sydney.
Founded in Singapore in 2017, Antler is on a mission to fundamentally improve the world by enabling and investing in the world's most exceptional people, by building complementary co-founder teams, supporting the teams with deep business model validation and providing a global platform for scaling. To date, Antler has invested in over 350 companies globally across 30 different industries. Of these companies, 40% have at least one female co-founder, and the founders represent 70 nationalities. Antler’s current portfolio of startups includes: HomeBase, Reebelo, Qashier, Volopay, Pathzero, Marco Financial , Xanpool, PowerX, and Xailient.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005689/en/
Contact information
Ben Goldsmith
ben@goldsmithcomms.com
+44(0)7788295321
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
